Trending...
- Shedrack Anderson Releases New Album
- Lansdowne Photographer Steven Weisz Selected for Philadelphia City Hall Exhibition
- Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
PHILADELPHIA, Nov. 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: https://www.prnewswire.com/news-releases/#finan..." rel="nofollow">CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Thursday, December 5th at 9:35 am ET.
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
More on The PennZone
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.
Investors:
Shveta Dighe
Head of Investor Relations
[email protected]
Media Contact:
Julia Stern
(763) 350-5223
[email protected]
SOURCE Carisma Therapeutics Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
More on The PennZone
- AI-Powered Trading Bots Are Transforming Forex, Gold, and Digital Markets as DefiHash Expands Intelligent Quantitative Infrastructure
- Early Bird Registration Open for FLYING HY, the Top Hydrogen and Battery Electric Aviation Event
- Eichelberger Performing Arts Center Welcomes New Executive Director
- Century Fasteners Corp. Hires Tony Marano as Director of Human Resources
- Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.
Investors:
Shveta Dighe
Head of Investor Relations
[email protected]
Media Contact:
Julia Stern
(763) 350-5223
[email protected]
SOURCE Carisma Therapeutics Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
Filed Under: Business
0 Comments
Latest on The PennZone
- Curious About Mensa? DFW Event Offers a 1-Day Immersion
- Morphy's will breeze into summer with a June 10-11 Fine & Decorative Arts auction featuring nearly 1,200 high-quality lots
- L-Tron to Exhibit at American Association for Motor Vehicle Administrators Region 1 Conference
- Buzzblender Announces Launch of Simple Hotel Mode for Android and Upcoming Video Wall Support for Samsung Professional Displays
- How Strategic WooCommerce Development and Digital Marketing Helped a Fashion Ecommerce Business Increase Revenue by 3X
- Burkentine Builders Breaks Ground For Two New Communities
- VIV Welcomes Residents to St. Petersburg's EDGE District
- Evocative Joins the Independent Data Centre Network (IDCN) as Primary USA Operator
- Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
- Medical Experts Highlight the Importance of Second Opinions in Death Investigations
- Joseph Nybyk aka Neibich of Gilbert, Arizona
- Omnitronics Unveils 100% Software omniGateDMR and omniGateP25 RoIP Gateways
- KRE PRIME Launches Adaptive Convertible Jumpsuit
- USA Med Bed Helping Home Care Patients with Refurbished Hill Rom Hospital Beds
- Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
- CAPHRA warns Southeast Asia not to repeat Australia's nicotine policy failure
- Milo3D.ai Launches Free AI 3D Model Generator That Turns Text and Images Into Game-Ready 3D Assets in Seconds
- UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
- Blank Space: The Unofficial Taylor Swift Tribute Brings Eras Tour Magic To Cities Across America
- Love Must Be the Guide: Live Good Shares a Message of Humanity, Compassion and Hope